The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Sep. 30, 2:35 PM

Slide #2. VolitionRx Limited Secondary Offering

Company: VolitionRx Limited (AMEX:VNRX)
Date announced: 9/29/2016
Shares Offered: 2,250,000
Date of Pricing: 9/30/2016
Price Per Share: $5.00
Secondary Offering Details: VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Volition intends to grant the underwriters a 30-day option to purchase an additional 15% of the shares of common stock sold in the offering, to cover over-allotments, if any. All shares of common stock in the offering are being offered by Volition. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 9/29- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer, today announced the pricing of its previously announced underwritten public offering of 2.25 million shares of common stock at a public offering price of $5.00 per share, resulting in gross proceeds of approximately $11.25 million. The offering is expected to close on or about October 5, 2016, subject to the satisfaction of customary closing conditions. Volition has granted the underwriters a 30-day option to purchase up to 337,500 additional shares of common stock to cover over-allotments, if any.

VolitionRx is a clinical-stage life sciences company focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. As of Dec 31 2015, using its Nucleosomics® technology, Co. had developed 28 epigenetic NuQ® assays, which was designed to detect the level and structure of nucleosomes in blood. These blood assays fall into five main types: NuQ®-X; NuQ®-V; NuQ®-M; NuQ®-A; and NuQ®- T. Co. is in the process of developing HyperGenomics® tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the therapy.
Open the VNRX Page at The Online Investor »

Company Name:  VolitionRx Ltd
Website:  www.volitionrx.com
Sector:  Medical Instruments & Supplies
Number of ETFs Holding VNRX:  1
Total Market Value Held by ETFs:  $13217
Total Market Capitalization:  $132.00M
% of Market Cap. Held by ETFs:  0.01%
 

Open the VNRX Page at The Online Investor (in a new window) »

September 30, 2016    2:35 PM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
90th percentile
(ranked higher than approx. 90% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.